## CVS: CVS Health Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 2.3% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 4, Bearish: 1)

**1. CVS Stock Gains From Offering MMR Vaccine to South Carolina Residents**
- Source: TradingView â€” Track All Markets | 20251215T140828 | Bullish | Relevance: 100%
- CVS Health has seen its stock rise after announcing the offering of measles-mumps-rubella (MMR) vaccines to South Carolina residents following a recent outbreak. The initiative, provided through CVS Pharmacy stores and MinuteClinic locations, aims to protect against measles and is expected to further boost the company's stock performance. This move aligns with CVS's broader strategy to enhance consumer-centric healthcare and follows a strong segment revenue growth in Q3 2025.

**2. Park National Corp OH Has $13.01 Million Holdings in CVS Health Corporation $CVS**
- Source: MarketBeat | 20251216T123416 | Bullish | Relevance: 100%
- Park National Corp OH reduced its stake in CVS Health Corporation by 8.9%, holding 172,605 shares valued at $13.01 million. Despite this, CVS Health reported strong quarterly results, beating EPS and revenue estimates, and received a "Moderate Buy" consensus rating from analysts with a $93.71 price target. The company also declared a quarterly dividend of $0.665.

**3. National Bank of Canada FI Sells 83,710 Shares of CVS Health Corporation $CVS**
- Source: MarketBeat | 20251215T102514 | Bullish | Relevance: 100%
- National Bank of Canada FI recently decreased its stake in CVS Health Corporation by selling 83,710 shares, now holding 1,177,825 shares valued at $81.23 million. This comes as CVS Health shows strong financial performance, beating quarterly earnings expectations with $1.60 EPS and $102.87 billion in revenue, and offering a 3.3% dividend yield. Analysts maintain a "Moderate Buy" consensus with an average price target of $93.71, reflecting confidence in the company's outlook.

**4. TD Cowen Increases CVS Health (NYSE:CVS) Price Target to $105.00**
- Source: MarketBeat | 20251213T151412 | Bullish | Relevance: 100%
- TD Cowen has raised its price target for CVS Health (NYSE:CVS) to $105.00 from $100.00 and maintained a "buy" rating, indicating a potential 30.63% upside. Several other brokerages have also increased price targets or reiterated positive ratings following CVS's strong Q3 earnings beat and positive FY2025 guidance. CVS Health reported earnings of $1.60 per share on revenue of $102.87 billion, surpassing analyst expectations.

**5. Press Release: Marsha Blackburn Questions CVS on Rising Health Care Costs and Fraud Allegations**
- Source: Quiver Quantitative | 20251216T023000 | Bearish | Relevance: 100%
- U.S. Senator Marsha Blackburn has sent a letter to CVS Health CEO David Joyner, raising concerns about the company's regulatory violations and its contribution to rising healthcare costs. Blackburn's "Patients Before Middlemen Act" aims to lower prescription drug costs by changing how pharmacy benefit managers like CVS Caremark operate. She further highlighted CVS's failure to cooperate with a Tennessee state audit, which resulted in fines, emphasizing the need for greater scrutiny of CVS's practices and transparency.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Bernstein | $87 | $86 | +1% |
| 2025-12-10 | Truist Securiti | $98 | $95 | +3% |
| 2025-12-10 | Piper Sandler | $101 | $99 | +2% |
| 2025-12-10 | UBS | $97 | $96 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Bernstein | main | Market Perform |
| 2025-12-10 | Truist Securiti | main | Buy |
| 2025-12-10 | Piper Sandler | reit | Overweight |
| 2025-12-10 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 11 ($1.40M) |
| Sells | 4 ($2.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 9.4% (-2.3%)
- Vanguard Group Inc: 9.4% (-1.3%)
- Dodge & Cox Inc.: 5.8% (-0.1%)
- JPMORGAN CHASE & CO: 5.6% (+162.5%)
- Capital World Invest: 5.4% (+2.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +6%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.56 indicates undervaluation relative to growth. Analyst sentiment positive (9 raises, avg +6%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $101.2B |
| Beta | 0.48 |
| 52W Range | $43.56 - $85.15 |
| Short Interest | 1.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.56 |
| Forward P/E | 11.1 |
| Current P/E | 12.0 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.8% to 2.3% (+4.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.7pp (needs >4.0% for momentum thesis). MRS_5 at 1.9% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.32% (CS: 54) | Neutral |
| RSI_14 | 54.4 | Neutral |
| MACD Histogram | 0.29 | Bullish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.136x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.69
- **Stop Loss:** $75.63 (5.1% risk)
- **Target:** $83.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 295
- **Position Value:** $23,508.55
- **Portfolio %:** 23.51%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $0.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.36 | $1.60 | +17.9% |
| 2025Q2 | $1.46 | $1.81 | +23.8% |
| 2025Q1 | $1.67 | $2.25 | +34.5% |
| 2024Q4 | $0.92 | $1.19 | +29.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*